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1. Introduction 
The extracellular matrix (ECM) is the cell structural environment in tissues and organs. The 
ECM is a dynamic structure that it is constantly remodelled. It contributes to tissue integrity 
and mechanical properties. It is also essential for maintaining tissue homeostasis, 
morphogenesis and differentiation, which it does, through specific interactions with cells. 
The ECM is composed of a mixture of water and macromolecules classified into four main 
categories: collagens, proteoglycans, elastic proteins, and non-collagenous glycoproteins 
(also called adhesive glycoproteins). The nature, concentration and ratio of the different 
ECM components are all important factors in the regulation of the assembly of complex 
tissue-specific networks tuned to meet mechanical and biological requirements of tissues.  
Collagens form a superfamily of 28 trimeric proteins, distinguishable from the other ECM 
components by their particular abundance in tissues (collagens represent up to 80-90% of 
total proteins in skin, tendon and bones) and their capacity to self-assemble into 
supramolecular organized structures (the best known being the banded fibers). The collagen 
superfamily is highly complex and shows a remarkable diversity in structure, tissue 
distribution and function (Ricard-Blum and Ruggiero, 2005).  
The importance of collagens has been illustrated by the wide range of mutations in collagen 
genes that result in minor and severe human diseases. Various mutations (point, null or 
structural mutations, insertions, exon skipping, deletions) in genes encoding collagens are 
known to be responsible for a large spectrum of human disorders (e.g., Elhers-Danlos 
syndrome, epidermolysis bullosa, chondrodysplasia, osteogenesis imperfecta, Alport 
syndrome, Bethlem myopathy, Ulrich congenital muscular dystrophy, Fuchs' endothelial 
dystrophy, Knobloch syndrome) that affect different tissues and organs, such as skin, blood 
vessels, cartilage, bones, kidney, muscle, cornea and retina. Considering the variety of 
collagen-related diseases and the complexity of collagen biology, there is a clear need to 
understand how mutations alter collagen synthesis, cell trafficking, cell and molecular 
interactions to result in tissue dysfunction.  In the eighties targeted mutagenesis emerged as 
a new approach to help establish the structure-function relationship of collagens. Along 
with the emergence of protein engineering and genetically modified mice, site-directed 
mutagenesis has become instrumental in understanding the physiopathology of diseases, as 
well as in developing new and specific therapies and drugs for the treatment of human 
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diseases. To date about 20 distinct genes encoding collagen chains have been ablated (by 
knock-out mutations) in mice or are involved in naturally occurring mutations. Only a few 
knock-in modified mice has been generated, in which a single point mutation or an exon 
deletion, for example, has been generated in a specific gene. This is likely due to the very 
large size of collagen genes. Site-directed knock-in mutations in mice have often proven to 
be more useful than knock-out mutations (which inactivate genes) for the analysis of the 
genotype-phenotype relationship, since small mutations represent the primary bases of 
inherited diseases. 
The aim of this chapter is to describe the use of targeted mutagenesis in the understanding 
of the physiopathology of inherited connective tissue disorders. Specifically we are 
concerned with mutations in collagen genes. We will focus on the use of site-directed 
mutagenesis to analyze the causative effects of human-identified collagen gene mutations. 
Recombinant molecules were used to analyze the effects of these mutations on collagen 
structure, biosynthesis, posttranslational modifications and interactions with binding 
partners and cells. This work has considerably improved our knowledge in development 
and in human disorders. These results will then be compared with the limited information 
about the introduction of subtle targeted mutations into murine collagen genes. 
2. The collagen superfamily at a glance 
The 28 members of the collagen superfamily exhibit considerable complexity and diversity 
in structure, assembly and function. However, collagens also share common features. (i) All 
members are modular proteins composed of collagenous (COL) domains flanked by non 
collagenous (NC) domains or linker regions. (ii) They are trimeric molecules formed by the 
association of three identical or different -chains, which are characterized by repetitions of 
the G-x-y tripeptide (with the x and y positions often occupied by proline and 
hydroxyproline, respectively). (Abbreviations and single-letter codes for amino acids are 
given in Table 1 of the chapter by Figurski et al.) (iii) They are able to assemble into 
supramolecular aggregates in the extracellular space, although this property has not been 
proven for all recently identified collagen members. Collagens also undergo various post-
translational modifications, including proteolytic processing, fibril formation, reticulation, 
shedding of transmembrane collagens and production of functional domains (also called 
matricryptins) (Ricard-Blum and Ruggiero, 2005). The mechanisms of collagen biosynthesis 
are far from being completely understood. Our knowledge is primarily based on the 
biosynthesis of fibril-forming collagens. Triple-helix formation commonly starts at the C-
terminus (C-propeptide) of the -pro-chain and proceeds toward the N-terminus (N-
propeptide) in a zipper-like fashion. Prior to and simultaneously with triple-helix formation, 
specific prolines and lysines are chemically modified by addition of hydroxyl group. These 
modifications play a pivotal role in stabilization and resistance to temperature. Completed 
trimeric procollagens are secreted from the cells, proteolytically processed and assemble 
into collagen fibrils (Ricard-Blum and Ruggiero, 2005). 
Based on their structure and supramolecular organization, collagens have been divided into 
several subfamilies (Myllyharju and Kivirikko, 2001). They are (i) the fibril-forming 
collagens I, II, III, V, XI, XXIV and XVII, which share the capacity to assemble into organized 
fibrils; (ii) the network-forming collagens IV, VIII and X and the FACIT (Fibril-Associated 
Collagen with Interrupted Triple-helix collagens) collagens IX, XII, XIV, XVI, XIX, XX, XI 
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and XXII, which are known to mediate protein-protein interactions; (iii) the basement 
membrane multiplexin (multiple triple-helix domains and interruptions) collagens XV and 
XVIII; (iv) the transmembrane collagens, including the neuronal XXV collagen and types 
XIII, XVII, XXIII; and finally (v) other unconventional collagens, such as the anchoring fibrils 
collagen VII and the ubiquitous collagen VI, which assembles into characteristic beaded 
filaments (Table 1). 
The length of the triple helical domains varies noticeably among different collagen types. 
Fibril-forming collagens consist of a long central COL domain with about 1000 amino acids 
(330 G-x-y tripeptide repeats), flanked by small terminal globular extensions (NC domains). 
After proteolytic processing of the N and C-terminal extensions, the mature molecules 
aggregate into highly ordered fibrils with a banded pattern observable by transmission 
electron microscopy. In other collagens, the COL domains are shorter and/or contain 
interruptions. The NC domains can represent the main part of the molecule, as for the 
FACIT collagen XII. Most, if not all, collagen types are recognized by specific cell receptors, 
such as the major ECM integrin receptors, collagen-specific discoidin domain receptors 
(DDR) and the transmembrane proteoglycan syndecans (Humphries et al., 2006; Xian et al., 
2010; Leitinger et al., 2007). Through various interactions with these cell receptors, collagens 
can induce intracellular pathways directly or indirectly and regulate cell functions, such as 
migration, proliferation and differentiation. Certain collagens can also bind to growth 
factors and control their bioavailability by acting as reservoirs. The controlled release of 
growth factors by proteolytic activity or expression of a splice variant that does not contain 
the binding site controls morphogenesis, as described for the cartilage collagen II (Zhu et al., 
1999).  
3. A large spectrum of mutations in collagen genes causes inherited 
disorders 
A myriad of mutations has been characterized in collagen genes (Table 1). The function of 
the gene product and its tissue localization are criteria that lead to a number of inherited 
connective tissues disorders (reviewed in Bruckner-Tuderman and Bruckner, 1998; Bateman 
et al., 2009). Typically mutations in collagen genes are null-mutations, i.e., those resulting in 
the translation of an -chain that cannot assemble into a triple helix and is consequently 
degraded intracellularly. Null mutations reduce the overall quantity of collagen in tissue 
and generally cause a human disorder. Small deletions and base substitutions can lead to 
synthesis of a mutated -chain that is able to form a triple helix. The molecule is secreted, 
but its structure is compromised for supramolecular assembly, which normally occurs in the 
extracellular space. In fine collagen gene mutations result in defective matrix assembly and 
organization that in turn can affect cell function (Figure 1). In cases of large multimeric 
molecules, such as collagens, dominant-negative mutations can be more deleterious than 
null mutations. However, a growing body of evidence shows that the synthesis of a large 
quantity of abnormal collagen molecules in cells during development can induce 
endoplasmic reticulum stress, with consequences ranging from cell recovery to death (Tsang 
et al., 2010). The correlation between phenotype severity and the location of a point mutation 
in the gene is not clear. However, a mutation located in the coding region for the amino-
terminus of the fibrillar collagen triple helix generally results in a mild phenotype, whereas 
a mutation in the coding region for the carboxy-terminus of the molecule is often lethal. This 
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observation may be related to the C- to N-terminus directional propagation of the triple 
helix and the role of the C-propeptides in -chain registration and triple helix nucleation. 
The nature of glycine substitution in the G-x-y repeats and the neighboring amino-acid 
sequence may have different biochemical and clinical consequences. These consequences 
include (i) delay of the triple-helix formation and over-glycosylation (Raghunath et al., 1994); 
(ii) alteration of procollagen processing (Lightfoot et al., 1994); (iii) retention of unfolded 
abnormal proteins intracellularly, leading to ER stress; and (iv) formation of abnormal 
unstable trimeric molecules, leading to disrupted fibrillogenesis.  
The presence of a glycine in every third position is critical for triple-helix formation, since 
only glycine, the smallest amino acid, fits into the center of the triple helix. The majority of 
dominant-negative mutations in collagen genes are due to replacements of one of the 
glycines in the collagenous domains of the -chains with a larger amino acid. Glycine 
substitution mutations in collagen genes underlie heritable connective tissue diseases, such 
as osteogenesis imperfecta (OI), chondrodysplasias, certain subtypes of Ehlers-Danlos 
syndrome (EDS), or Alport’s syndrome (reviewed in Bruckner-Tuderman and Bruckner, 
1998; Bateman et al., 2009). Since a non-glycine amino acid does not easily fit into the interior 
space of the triple helix, helix formation is distorted, thereby affecting its structure and 
stability and impeding fibrillogenesis. Delay in triple-helix formation can result in over-
modification and may affect collagen function. 
Osteogenesis imperfecta (OI), also known as brittle bone disease, is caused by mutations in 
genes for collagen I, the most abundant collagen in organisms. OI is characterized by fragile 
bones that break easily and reduced bone mass. Most OI cases are believed to be associated 
with glycine substitution mutations in the COL1A1 or COL1A2 genes.  Over 200 mutations 
have been reported for the COL1A1 (located on chromosome 17) and COL1A2 (located on 
chromosome 7) genes, which code for the collagen I pro-1 and pro-2 chains, respectively.  
This fact may explain the wide range of clinical characteristics and degrees of severity that 
are seen in the disease (Kuivaniemi et al., 1991, Byers and Steiner 1992, Dalgleish, 1998). 
Because collagen I is found in other tissues of the body, OI has non-skeletal manifestations 
as well. People with OI may also suffer from muscle weakness, hearing loss, fatigue, joint 
laxity, distensible skin, or dentinogenesis imperfecta. The fibril-forming collagen I is mostly 
synthesized as the [1(I)]22(I) heterotrimer chain, though a minor form [1(I)]3 is expressed 
in embryonic tissues. COL1A1 and COL2A1 are both susceptible to various mutations 
responsible for the production of quantitatively or qualitatively deficient fibrils. The clinical 
severity of OI relates to the extent of the conformational change in the collagen triple helix 
induced by the glycine substitution.  These mutations result in altered fibrillogenesis. 
However, no general mechanism can be drawn from genotype/phenotype analyses.   
Collagen VII, encoded by COL7A1, is the major component of the anchoring fibrils at the 
dermo-epidermal junction (Burgeson, 1993). COL7A1 gene mutations cause dystrophic 
epidermolysis bullosa (DEB), a skin-blistering disorder (Bruckner-Tuderman, 1999). 
Approximately 200 mutations of COL7A1 have been characterized, leading to a very high 
molecular heterogeneity of collagen VII defects (Dunnill et al., 1996). Almost all cases of 
dominant DEB are caused by a glycine substitution in the triple helical region of collagen 
VII, and most of the mutations are unique to individual families. Some glycine substitutions 
in collagen VII interfere with biosynthesis of the protein in a dominant-negative manner, 
whereas others may lead to collagen VII retention within the rough endoplasmic reticulum.  
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Mutations in the COL5A1 and COL5A2 genes, encoding respectively the pro-1 and pro-2 
chains of the fibril-forming collagen V, have been identified in approximately 50% of 
patients with a clinical diagnosis of classic Ehlers-Danlos syndrome (EDS) (Malfait et al., 
2010). Collagen V contains a third chain, pro3(V); but no mutation in COL5A3 has been 
reported so far. Classic EDS is a heritable disorder of connective tissues characterized by 
skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of 
atrophic scars, easy bruising, and generalized joint hypermobility. The majority of 
mutations lead to a non-functional COL5A1 allele. One mutant COL5A1 transcript showed a 
premature stop codon. A minority of mutations affect the structure of the central helical 
domain. In approximately one-third of patients, the disease is caused by a mutation leading 
to a non-functional COL5A1 allele, resulting in collagen V haploinsufficiency. Structural 
mutations in COL5A1 or COL5A2, resulting in the production of a functionally defective 
protein, account for a small proportion of patients. 
Collagen V is a quantitatively minor fibril-forming collagen that co-polymerizes with 
collagen I to form heterotypic fibrils (Fichard et al., 1995). Co-polymerisation has a critical 
role in the nucleation and growth of fibrils in tissues. A collagen V feature is to retain in the 
mature molecule a major part of the 1(V) N-propeptide which projects beyond the surface 
of collagen fibrils. This domain was proposed to limit heterotypic fibril growth by steric 
hindrance and electrostatic interactions (Linsenmayer et al., 1993). Skin biopsies revealed 
abnormalities in fibril formation (altered diameter, contour, or shape of dermal fibrils). 
However, abnormalities of fibril structure affected less than 5% of fibrils (reviewed in 
Fichard et al., 2003). Moreover, the clinical phenotype of classical EDS supports an important 
role of collagen V in the biomechanical integrity of the skin, tendon and ligaments, although 
collagen V is only a minor component of the affected tissues.  Thus, collagen V may be 
involved in functions other than the control of fibril growth in classical EDS. A likely 
hypothesis is that collagen V might be involved in the physiopathology of EDS through 
interactions with other fibril-associated components and/or with cell receptors. Along this 
line, it has been shown that mutations in the genes for the collagen V-binding partners, 
tenascin-X (TNXB gene) and collagen I (COL1A1 gene), resulted in EDS (Lindor and Bristow, 
2005).  
Although mutant gene products are thought to impair matrix structure and assembly that 
eventually alters tissue function, growing evidence links ER stress and the unfolded 
protein response (UPR) to the initiation and progression of a broad repertoire of 
connective tissue disorders, including those caused by collagen gene mutations. Some 
mutant chains cannot be incorporated into procollagen molecules, consequently causing 
protein degradation with important downstream effects. Misfolded or slowly folding 
collagens are retained within the endoplasmic reticulum (ER) and ultimately targeted for 
degradation by a mechanism initially called “protein suicide.” Because connective-tissue 
cells typically produce large quantities of collagens, the contribution of ER stress induced 
by misfolded collagens in disease pathogenesis has certainly been underrated. The current 
knowledge on the implications of unfolded protein response and ER stress in connective 
tissue diseases has been recently reviewed, and readers are referred to these reviews for 
further reading (Boot-Handford and Briggs, 2010; Tsang et al., 2010). Notably, mutations 
in genes encoding collagen I (COL1A1 and COL1A2) (osteogenesis imperfecta), collagen II 
(COL2A1) (spondyloepiphyseal dysplasia), and collagen X (COL10A1) (metaphyseal  
 





Table 1. Collagen types, associated-diseases and mouse models. 
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chondrodysplasia) have been shown to induce ER dilatation in patient cells. Mutations that 
affect the triple helix, the C-propeptide for the fibril-forming collagens, and splice donor 
sites, as well as single amino-acid substitutions, were shown to cause ER stress.  Recently, 
mutations that affected the signal peptide domain of the pro1(V)-collagen chain were 
shown to cause classic EDS. The signal peptides are the addresses of proteins destined for 
secretion. The mutant procollagen V is retained within the cell, leading to a collagen V 
haploinsufficiency and altered collagen fibril formation. It is probable that the signal peptide 
mutation also causes accumulation of the mutated protein within the ER and eventually to 
ER stress, as described for other collagen-related disorders (Symoens et al., 2009).  
 
Fig. 1. Schematic diagram illustrating the biological consequences of point mutations or 
small deletions in collagen genes on chain synthesis, protein folding and subsequent fibril 
assembly in the extracellular matrix. 
Mutations in the three major collagen VI genes (COL6A1, COL6A2 and COL6A3) cause 
multiple muscle disorders, including the severe Ullrich congenital muscular dystrophy 
(UCMD) and the mild Bethlem myopathy, which is characterized by muscle weakness with 
striking joint laxity and progressive contractures. Three genetically distinct novel chains 
4(VI), 5(VI), and 6(VI) have recently been identified; but very little is known about their 
molecular assembly and biosynthesis and their possible involvement in human diseases 
(Gara et al., 2011).  Collagen VI biosynthesis is a complex multistep process. Monomer 
formation results from the heterotrimeric association of the three chains [1(VI), 2(VI), and 
3(VI)] encoded by the COL6A1, COL6A2 and COL6A3 genes. Monomers first assemble into 
antiparallel dimers that associate laterally to form tetramers stabilized by disulphide bonds. 
The tetramers associate linearly to form the unique beaded filaments, the ultimate step of 
collagen VI biosynthesis. Dominant and recessive autosomal mutations in COL6A1, 
COL6A2, and COL6A3 primarily result in dysfunctional microfibrillar collagen VI in muscle 
extracellular matrix. However they also affect other connective tissues, such as skin and 
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tendons. Different mutations have been shown to have variable effects on protein assembly, 
secretion, and its ability to form a functioning extracellular network. As observed in other 
collagen-related diseases, glycine-substitution mutations in COL6A1, COL6A2, or COL6A3 
that disrupt the triple-helix motif constitute a frequent pathogenic mechanism. Triple-helix 
distortion may exert a dominant-negative effect by reducing the ability of mutated 
monomers to form beaded filaments. Interestingly, mitochondrial dysfunction was 
implicated in the pathogenesis of a myopathic phenotype. Muscles lacking collagen VI are 
characterized by the presence of a dilated sarcoplasmic reticulum and dysfunctional 
mitochondria. This condition triggers apoptosis and leads to myofiber degeneration. 
Recently, it was shown that the persistence of abnormal organelles and apoptosis observed 
in some congenital muscular dystrophies are caused by defective activation of the 
autophagic machinery. Autophagy has a key role in the clearance of damaged organelles 
and in the turnover of cell components and is thus essential for tissue homeostasis. Recently, 
56 novel mutations have been described, allowing a clinical classification and revealing the 
complexity of genotype-phenotype relationships (Briñas et al., 2010). 
The paucity of evidence-based data regarding correlations of genotype and phenotype is in 
part due to the large spectrum of mutations reported for the collagen genes [e.g., about 200 
mutations for the collagen I genes responsible for OI (Dalgleish, 1998); 160 mutations in the 
COL4A5 gene encoding collagen IV 5 chain responsible for Alport syndrome; 200 mutations 
in COL7A1 responsible for EDB]. Things are not as simple as one gene-numerous mutations-
one phenotype. Sometimes a combination of a mutation for a connective tissue disorder and a 
specific collagen gene mutation will result in another disease. Some patients with UCMD 
show clinical characteristics typical of classical disorders of connective tissue, such as EDS. 
Ultrastructure of skin biopsy samples from patients with UCMD showed alterations of 
collagen fibril morphology in skin that resemble those described in patients with EDS 
(Kirschner et al., 2005). Recently, using the yeast two-hybrid approach, we showed a direct 
interaction between collagen V and collagen VI that may nicely explain the overlap of UCMD 
and classic EDS (Symoens et al., 2011). Unexpectedly an arginine-->cysteine substitution 
localized at position 134 of the 1(I) collagen chain resulted in classical EDS (Nuyntick et al., 
2000). This finding is indicative of genetic heterogeneity in collagen-related disorders.  
A powerful approach to study the biochemical consequences of mutation and the protein 
structure/function relationship is to engineer a specific mutation into a functional domain of 
the molecule. Targeted mutagenesis approaches, including the use of alanine-scanning 
mutagenesis techniques, have led to important insights into the effects of collagen mutations 
on protein structure and function. A major limitation of mutagenesis strategies to 
investigate collagens is the large number of collagen gene mutations to be investigated in 
order to have a better understanding of the molecular mechanisms of “collagenopathies.” 
Knowledge about the impact of collagen mutations has also been hampered by the technical 
difficulty of introducing targeted mutations of very large collagen genes into mice.  
4. Lessons from site-directed mutagenesis of recombinant collagen genes 
and derived fragments 
Production of a recombinant collagen gene represents a powerful technique to introduce a 
human mutation into the gene of interest by site-directed mutagenesis. It allows one to 
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analyze the impact of the mutation on collagen assembly and secretion. Collagen 
biosynthesis is a complex multistep process that takes place in the intracellular and 
extracellular space and includes various post-translationnal modifications, such as prolyl- 
and lysyl-hydroxylation, glycosylation, trimerization, proteolytic processing, 
polymerization and cross-links. Because of recombinant technology, these large multimeric 
proteins have been produced in large amounts in almost all existing expression systems 
(Ruggiero and Koch, 2008). This technological breakthrough enabled researchers to analyze 
in detail the effects of collagen mutations on biosynthesis, molecular and cell interactions, 
processing and, in some cases, self-assembly. Researchers can also address the question of 
the correlation of genotype, protein structure and function. 
Mutations occurring in collagen I genes are the most extensively studied mutations among 
all collagen types. A first set of experiments substituted glycine 859 of the pro1(I) chain 
with cysteine or arginine by site-directed mutagenesis to reproduce two mutations 
identified in OI patients. In order to study the expression of the mutant molecule in the 
presence or absence of the wild-type pro1(I) chain, the mutated constructs were transfected 
into normal fibroblasts to look for a dominant-negative effect in the presence of the wild-
type gene or in fibroblasts isolated from Mov13 homozygous mice (referred to as Mov13 
fibroblasts hereafter), whose cells carry a provirus that prevents transcription initiation of 
the natural pro1(I) gene (Schnieke et al., 1987). In agreement with observations of collagen I 
in OI patients, the mutated collagens were poorly secreted from the cells and exhibited 
reduced thermal stability and increased sensitivity to degradation. This supported the idea 
that the strict preservation of the G-x-y triplets is absolutely required for proper formation 
of the triple helix.  
The integrity of the C-propeptide is pivotal for the trimerization of all fibril-forming 
collagens. The C-propeptides of the pro1(I) and pro2(I) chains contain an Asn-Ile-Thr 
sequence.  That sequence fits a consensus sequence for the addition of N-linked 
oligosaccharides. To analyze the role of this post-translational modification, the asparagine 
residue of the pro1(I) chain was changed to glycine by site-directed mutagenesis. The 
expression of the corresponding molecule was analyzed in transfected normal and Mov13 
fibroblasts (Lamandé and Bateman, 1995). The mutation did not impair heterotrimeric 
assembly and secretion of hybrid procollagen I into the extracelllular space. Only a slight 
effect on C-proteinase cleavage efficiency was observed with the unglycosylated molecule. 
To circumvent the difficulty of producing a large repertoire of full-length mutated collagens 
I in order to undertake a genotype/phenotype analysis, a recombinant trimeric mini-
collagen I was recently expressed in an Escherichia coli system.  Recombinant mini-collagens 
can be obtained by fusing the sequence encoding a fragment of the pro1(I) chain triple-
helix to the sequence encoding the C-terminal domain (called “foldon”) of the bacteriophage 
T4 fibritin, which is capable of trimerization (Xu et al., 2008). Two mutations (G901S and 
G913S), corresponding to mild and severe types of OI, respectively, were introduced into 
the recombinant mini-collagen I. Biophysical measurements and protease cleavage analysis 
revealed that the G913S mutant chain resulted in the formation of an unstable collagen I 
triple helix by disrupting salt bridges important for maintaining the chains in a triple-helix 
conformation (Yang et al., 1997; Xu et al., 2008). A very recent study utilized a recombinant 
bacterial collagen to develop a mutagenesis scheme in which a glycine residue within the 
triple-helix sequence is substituted with arginine or serine. The purpose was to analyze the 
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positional effect of glycine mutations on triple-helix formation and stability (Cheng et al., 
2011).  Interestingly, all glycine mutations provoked a significant delay in the triple-helix 
formation. However, a more severe defect was observed when the mutation was located 
near the trimerization domain of the triple-helix where folding is initiated.  
COL7A1 mutations cause dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. 
Woodley and collaborators (2008) have used site-directed mutagenesis to elucidate the effect 
of human mutations on the function of collagen VII, which is the major component of the 
epidermal anchoring fibrils. To undertake a comprehensive analysis of the impact of human 
mutations in the formation, folding and stability of collagen VII and, particularly relevant to 
the DEB phenotype, its effect on cell attachment and migration, four distinct substitutions 
occurring in collagen VII (G2049E, R2063W, G2569R, and G2575R) were introduced using 
COL7A1 cDNA. The authors demonstrated that the G2049E and R2063W mutants caused 
local destabilization of the triple helix and reduced the capability of collagen VII to elicit cell 
adhesion and migration. The G2569R and G2575R mutants interfered with triple-helix 
formation and stability. Alterations of protein stability and/or cell attachment to collagen 
VII mutants help explain the fragility of the dermal-epidermal junction observed in DEB 
patients. Naturally occurring COL7A1 mutations were investigated in a separate study 
(Hammami-Hauasli et al., 1998). As commonly described for glycine-substitution mutants of 
collagens, the authors showed that three glycine substitutions located in the same triple-
helix portion affected folding, stability and secretion of procollagen VII in a dominant-
negative manner. However, the glycine substitution G1519D located in another segment of 
the triple helix had no effect on procollagen VII secretion or its ability to anchor fibril 
assembly. These data showed that the biological impact of glycine substitutions can depend 
on their position within the triple helix, as shown for collagen I (Cheng et al., 2011). 
Human collagen IV mutations, thought to affect the biosynthesis of this basement 
membrane collagen, were extensively investigated. These mutations were known to cause 
Alport syndrome, a severe renal disease leading eventually to kidney failure. Collagen IV 
chains, 1(IV)-6(IV), are encoded by 6 genes, COL4A1-COL4A6, respectively.  Although 
mutations have also been identified in COL4A3 and COL4A4, about 30% of known missense 
mutations occur in the COL4A5 gene, which encodes the human 5(IV) chain. Most of them 
are glycine substitutions. One glycine-substitution mutation in COL4A5 could prevent 
correct -chain folding or/and the association with other -chains to form a stable triple 
helix. To address this question, the authors took advantage of the bacterial system. A DNA 
encoding a 22-kDa recombinant domain of the 5(IV) triple helix in its wild-type form or 
harboring the G1015V or G1030S mutations was expressed in E. coli (Wang et al., 2004). The 
recombinant wild-type and mutant proteins were purified and assayed for changes in triple-
helix assembly and stability by circular dichroism.  The two different glycine-substitution 
mutants displayed different defects in the secondary structures of their protein products 
that matched with the severity of the patient phenotypes. However, the use of a bacterial 
system to analyze the effects of specific human mutations on mini-collagen assembly and 
stability presents several disadvantages.  Because collagens are large multimeric proteins, 
full-length molecules cannot be produced in a bacterial host. Most importantly, the bacterial 
system is limited. Not all post-translational modifications needed for the triple-helix 
formation and stability, such as hydroxylation, glycosylation, and disulfide-bond formation, 
are present in bacteria. A few years later, the bacterial limitations were bypassed by the 
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development of the production of full-length recombinant collagen molecules in 
mammalian cells (Fichard et al., 1997; Ruggiero and Koch, 2008). No less than eighteen 
human mutations (11 substitutions and 7 deletions) were introduced into the sequence 
encoding the trimerization NC1 domain of the 5(IV) chain gene. The constructs were 
transfected into cells together with constructs containing the wild-type sequences of 3(IV) 
and 4(IV) chains to analyze the impact of the mutations in the NC1 domain on the 
formation of the 345 collagen IV heterotrimer. Twelve out of 15 mutant chains did loose 
their capacity to assemble into heterotrimeric molecules. The three remaining mutants 
formed heterotrimers, but the mutations prevented their secretion into the extracellular 
space (Kobayashi et al., 2008). The authors nicely demonstrated, using site-directed 
mutagenesis, that amino acid substitutions in the 5(IV) NC1 trimerization domain are 
specifically responsible for impairment of collagen IV heterotrimer assembly. This defect 
may be a main molecular mechanism for the pathogenesis of Alport syndrome. 
Interestingly, an interactome (a map of known and predicted molecular interactions, as well 
as phenotypic and structural landmarks) of collagen IV was recently constructed to identify 
functional and disease-associated domains and genotype-phenotype relationships (Parkin et 
al., 2011). Construction of such interactomes will greatly improve our capacity to integrate 
all data from different site-directed mutagenesis experiments. This advance will greatly help 
our understanding of the molecular mechanisms underlying “collagenopathies”; and, 
consequently, it may lead to the development of specific treatments. 
Collagens undergo a great variety of proteolytic modifications. The fate and functions of the 
released fragments derived from collagens are still under intensive investigation, but the 
consequences of mutations in the coding regions for the cleavage sites on collagen structure, 
self-assembly and function have not been investigated in detail. A large repertoire of 
proteinases is responsible for these processing interactions. Included among such enzymes 
are the ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) and the 
BMP-1/tolloid families of metalloproteinases and more recently the furin-like proprotein 
convertases (Ricard-Blum and Ruggiero, 2005). To investigate collagen processing, 
fastidious extraction and purification steps were often necessary to obtain limited amounts 
of unprocessed proteins and enzymes with full activity in order to undertake in vitro 
enzymatic assays. To circumvent this problem, we recently described a new cell system 
allowing a rapid and straightforward analysis of processing interactions. Our system relies 
on the use of site-directed mutagenesis. This strategy was particularly instrumental in 
analyzing the complex procollagen V processing during maturation. We showed it to be 
unique among the fibril-forming collagens (Bonod-Bidaud et al., 2007). Collagen V is a minor 
fibrillar collagen that can be distinguished from the others by its capacity to control 
fibrillogenesis (Fichard et al., 1995). In addition this molecule undergoes a particular form of 
processing; and it is involved in fundamental processes, such as development and human 
connective tissues disorders. The pro1(V) N-terminus can be processed by the procollagen 
proteinases ADAMTS-2 and BMP-1 (Colige et al., 2005; Bonod-Bidaud et al., 2007), whereas 
the C-propeptide can be cleaved by furin and BMP-1 (Kessler et al., 2001). The pro1(V) C-
propeptide furin cleavage site, which occurs immediately downstream of the recognition 
sequence RTRR, was double-mutated to alanine residues (R1584A/R1585A) to abolish furin 
cleavage. All constructs were introduced into cells, along with a BMP-1-expressing 
construct; and the cleavage products were directly analyzed in conditioned medium of the 
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transiently transfected cells. We were able to show that BMP-1 is capable of processing the 
1(V) C-propeptide in absence of furin activity (Bonod-Bidaud et al., 2007). In the same way, 
the determinant for 1(V) N-propeptide processing by BMP-1 activity was identified by 
introducing in the coding region for the cleavage site (S254/Q255-D256) three single 
mutations (S254A, Q255A and D256A), two double mutations (S254A/Q255N and 
Q255A/D256A) and one triple mutation (S254A/Q255A/D256A). The data highlighted the 
unexpected importance of the aspartic acid in the P2’ position of the BMP-1 cleavage site 
(Bonod-Bidaud et al., 2007). Processing, proteolytic release of functional domains and 
shedding of collagens are involved in fundamental processes. It is likely that substitutions 
located in the proteolytic cleavage sites may represent a molecular cause of connective 
tissues disorders. A reported mutation in the 1(V) N-propeptide in one patient with classic 
EDS resulted in a protein product missing the sequence of exon 5 that encompasses the 
BMP-1 cleavage site. The abnormal-sized N-propeptide present in the mutated collagen V 
caused dramatic alterations in fibril structure (Takahara et al., 2002).  
5. Lessons from site-directed mutagenesis in mice  
In vitro studies are useful and necessary approaches to understand the mechanisms of 
collagen biosynthesis and to establish structure-function relationship. However, they do 
not always reflect the normal and pathological in vivo situations. Genetically modified 
mice appear to be a powerful technique to better understand the physiopathology of 
connective tissue disorders. Several different genetically modified mice have been created 
during the last 10 years (reviewed in Aszódi et al., 2006). This clearly opened doors to 
better understand collagen function in developing tissues and provide reliable mouse 
models for inherited collagen diseases. Along this line, a targeted disruption of Col4a3 
gene led to renal failure and eventually to the death of mice at 3-4 months of age 
(Cosgrove et al., 1996; Miner and Sanes, 1996). This result is consistent with defects 
described for Alport disease.  
In most cases, the gene of interest was disrupted and knock-out mice were preferably 
generated.  Few transgenic mice harbouring point mutations or small deletion in collagen 
genes have been generated (Table 1). Naturally occurring mutations in mice disrupting 
collagen genes have also been identified and characterized. The oim mice present a 
spontaneously acquired deletion in the Col1a2 gene that leads to an accumulation of [(I)]3 
collagen homotrimer in the extracellular matrix. These mice develop a phenotype similar to 
moderate OI in humans, providing a good model for this collagen disorder (Chipman et al., 
1993). It was shown that homozygous Mov13 embryos harboring an inactivated pro1(I) 
chain  (due to the insertion of the Moloney murine leukaemia virus into the first exon of the 
Col1a1 gene) died in utero around day 12 because of vascular failure (Löhler et al.,  1984). 
However, in 1999 Forlino et al. developed the first knock-in mouse model for human OI by 
introducing a G349C mutation into the Col1a1 gene. Along this line, a knock-in mouse 
model for OI, harboring a point mutation (G610C) in Col1a2 was recently created (Daley et 
al., 2010). These mice had reduced body mass and bone strength and exhibited bone fracture 
susceptibility consistent with the clinical features of human OI. Thus, the G610C knock-in 
mouse represents a novel model for the study of OI pathogenesis and also for testing 
potential therapies for OI. 
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Another example concerns collagen V deficiency/dysfunction, which is responsible for 
Ehlers-Danlos syndrome (EDS). In the absence of the Col5a1 gene, the mice died at the onset 
of organogenesis at approximately embryonic day 10 (Wenstrup et al., 2004).  Interestingly, a 
targeted deletion in the Col5a2 gene, encoding the pro2(V) chain, recapitulated many of the 
clinical, biomechanical, morphologic, and biochemical features of the classical EDS. The 
deletion removes the sequence encoding the N-telopeptide (pN), a 20-residue region that 
confers flexibility to the N-terminal part of the molecule (Andrikopoulos et al., 1995). A 
detailed study of the skin at the morphological, histological, ultrastructural and biochemical 
levels indicated that the Col5a2 deletion impairs assembly and/or secretion of the 
[1(V)]22(V) heterotrimer. Consequently, the [1(V)]3 homotrimer, and not the 
[1(V)]22(V) heterotrimer, is the predominant species deposited into the matrix, which in 
turn severely impaired extracellular matrix organization (Chanut-Delalande et al., 2004). 
These data underscored the importance of the collagen V [1(V)]22(V) heterotrimer in 
dermal fibrillogenesis and can explain defects observed in the dermis of EDS patients.  
6. Concluding remarks  
Site-directed mutagenesis has been extensively used in collagen engineering and has shed 
light on collagen structure, expression, folding, secretion, interactions and self-assembly in 
the extracellular space. It also opened the way for the analysis of specific functional 
domains. It allowed the study of the wide variety of collagen types, including those 
expressed in trace amounts in tissues but nevertheless display pivotal functions. While it is 
true that site-directed mutagenesis has yielded important information on the functional 
consequences of a range of collagen mutations responsible for human diseases, only few 
studies have approached the consequences of collagen gene mutations on cell adaptation to 
ER stress. Collagen gene mutations affect protein synthesis, folding and secretion imbalance, 
which eventually induces ER stress. In vitro studies have been done on transfected cells, in 
which expression and trafficking of mutant collagen can be easily manipulated and 
analysed at the cellular level.  The effects of gene manipulation can be studied in vivo using 
mice. The effect of collagen gene mutations on induction of an ER stress response could be 
straightforwardly addressed in the near future. It may be a key factor in pathogenesis (Boot-
Handford and Briggs, 2010). 
Mouse models are particularly useful for analysing the biological significance of collagens in 
pathological situations. Knock-out mice often lead to embryonic lethality, which hampers 
in-depth analysis of the phenotype. A few knock-in mice have been created with subtle 
mutations or small deletions that reproduce human mutations. The major reason for the 
paucity of knock-in mice is certainly that collagen genes are very large. Thus, they are 
difficult to manipulate.  The introduction of a small deletion or a single point mutation in 
murine collagen genes still represents a considerable challenge. Nevertheless, the few 
examples of knock-in mouse lines tend to prove that mouse models can bring new 
information about in vivo consequences of collagen dysfunction that cannot be predicted by 
in vitro approaches. Knock-in mice are also indispensable models for assessing the effects of 
subtle mutations on tissue function, development, and aging. They are also valuable for 
developing specific gene therapy approaches to combat collagen-related disorders. The 
combination of site-directed mutagenesis in transfected cells and knock-in approaches in 
mice to address the impact of specific mutations will enable us to identify mechanisms 
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underlying the vast repertoire of collagen-related diseases. The implications may lead to the 
development of a specific therapy. 
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